201 related articles for article (PubMed ID: 22640460)
1. Chemotherapy and skin reactions.
Fabbrocini G; Cameli N; Romano MC; Mariano M; Panariello L; Bianca D; Monfrecola G
J Exp Clin Cancer Res; 2012 May; 31(1):50. PubMed ID: 22640460
[TBL] [Abstract][Full Text] [Related]
2. Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy.
Pinto C; Barone CA; Girolomoni G; Russi EG; Merlano MC; Ferrari D; Maiello E; ;
Oncologist; 2011; 16(2):228-38. PubMed ID: 21273511
[TBL] [Abstract][Full Text] [Related]
3. [New tyrosine kinase and EGFR inhibitors in cancer therapy. Cardiac and skin toxicity as relevant side effects. Part B: Skin].
Ehmann LM; Heinemann V; Wollenberg A
Internist (Berl); 2011 Nov; 52(11):1359-64. PubMed ID: 21796420
[TBL] [Abstract][Full Text] [Related]
4. Impact of dermatologic adverse reactions on QOL in oncologic patients: results from a single-center prospective study.
Barbu MA; Niţipir C; Voiosu T; Giurcăneanu C
Rom J Intern Med; 2018 Jun; 56(2):96-101. PubMed ID: 29360630
[TBL] [Abstract][Full Text] [Related]
5. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
[TBL] [Abstract][Full Text] [Related]
6. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
Ocvirk J; Cencelj S
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous toxicities of antineoplastic agents: data from a large cohort of Greek patients.
Nikolaou V; Voudouri D; Tsironis G; Charpidou A; Stamoulis G; Triantafyllopoulou I; Panoutsopoulou I; Xidakis E; Bamias A; Samantas E; Aravantinos G; Gogas H; Rigopoulos D; Syrigos K; Stratigos A
Support Care Cancer; 2019 Dec; 27(12):4535-4542. PubMed ID: 30919155
[TBL] [Abstract][Full Text] [Related]
8. Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.
Yalici-Armagan B; Ayanoglu BT; Demirdag HG
Cutan Ocul Toxicol; 2019 Sep; 38(3):261-266. PubMed ID: 31010330
[No Abstract] [Full Text] [Related]
9. Clinical and histopathologic correlation of an eruption secondary to Taxotere.
Beer K; Oakley H
J Drugs Dermatol; 2010 Dec; 9(12):1534-5. PubMed ID: 21120264
[TBL] [Abstract][Full Text] [Related]
10. Xerosis and pruritus as major EGFRI-associated adverse events.
Clabbers JMK; Boers-Doets CB; Gelderblom H; Stijnen T; Lacouture ME; van der Hoeven KJM; Kaptein AA
Support Care Cancer; 2016 Feb; 24(2):513-521. PubMed ID: 26111953
[TBL] [Abstract][Full Text] [Related]
11. Trichomegaly of the eyelashes during therapy with epidermal growth factor receptor inhibitors: report of 3 cases.
Fabbrocini G; Panariello L; Cacciapuoti S; Bianca D; Ayala F
Dermatitis; 2012; 23(5):237-8. PubMed ID: 23010833
[TBL] [Abstract][Full Text] [Related]
12. "I Lost My Image, the Image Others Know Me By": Findings From a Hermeneutic Phenomenological Study of Patients Living With Treatment-Induced Cutaneous Toxicities.
Charalambous A; Charalambous M
Res Nurs Health; 2016 Jun; 39(3):187-96. PubMed ID: 27080722
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors.
Osio A; Mateus C; Soria JC; Massard C; Malka D; Boige V; Besse B; Robert C
Br J Dermatol; 2009 Sep; 161(3):515-21. PubMed ID: 19466958
[TBL] [Abstract][Full Text] [Related]
14. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails.
Lacouture M; Sibaud V
Am J Clin Dermatol; 2018 Nov; 19(Suppl 1):31-39. PubMed ID: 30374901
[TBL] [Abstract][Full Text] [Related]
15. A prospective crossover pilot study to evaluate the use of a topical wound gel in patients with cutaneous toxicity caused by epidermal growth factor receptor inhibitors.
Wong SF; Lindgren A; Mummaneni M; Byun T; Vasko C; Arenos R; Alexson E; Osann K
J Support Oncol; 2010; 8(5):202-8. PubMed ID: 21086877
[TBL] [Abstract][Full Text] [Related]
16. Managing skin toxicities related to panitumumab.
Bergman H; Walton T; Del Bel R; Seki JT; Rafii A; Xu W; Koren G; Shear N; Krzyzanowska MK; Howell D; Liu G
J Am Acad Dermatol; 2014 Oct; 71(4):754-9. PubMed ID: 25085331
[TBL] [Abstract][Full Text] [Related]
17. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients.
Roé E; García Muret MP; Marcuello E; Capdevila J; Pallarés C; Alomar A
J Am Acad Dermatol; 2006 Sep; 55(3):429-37. PubMed ID: 16908348
[TBL] [Abstract][Full Text] [Related]
18. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic.
Rosen AC; Case EC; Dusza SW; Balagula Y; Gordon J; West DP; Lacouture ME
Am J Clin Dermatol; 2013 Aug; 14(4):327-33. PubMed ID: 23625802
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous adverse reactions of imatinib therapy in patients with chronic myeloid leukemia: A six-year follow up.
Dervis E; Ayer M; Akin Belli A; Barut SG
Eur J Dermatol; 2016 Apr; 26(2):133-7. PubMed ID: 26679005
[TBL] [Abstract][Full Text] [Related]
20. [Management of the cutaneous side effects of chemotherapies and targeted therapies].
Delyon J; Gerard M; Nicodeme M; Fromantin I; Loirat D
Soins; 2015 Jun; (796):17-24. PubMed ID: 26146316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
